Archive for December, 2020
NetworkNewsWire Editorial Coverage via CBDWire: CBD is now legal in all 50 states, and on election day this year, four states voted to legalize the recreational use of cannabis, bringing the total of states allowing recreational cannabis use to 15. This growing acceptance has fueled an influx of new CBD-infused products and brands, leading a Lido Consulting report to note that the total addressable cannabis market (TAM) could potentially hit $1 trillion in global economic impact by 2027. Savvy companies recognize the bright promise of this burgeoning industry and are focused on taking advantage of the massive opportunity. Leading the pack is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), which entered the CBD space with the launch of its A88CBD(TM) brand. Alkaline Water, which already had a nationally recognized line of premium bottled water and flavor-infused water, now offers a full line of CBD-infused and topical products. Others strengthening their positions in the space include Tilray Inc. (NASDAQ: TLRY), which through its wholly owned subsidiary High Park, has a portfolio of “Cannabis 2.0” brands and products. In addition, in a joint venture with Tilray, Anheuser-Busch InBev SA (NYSE: BUD) has announced plans to commercialize non-alcohol, CBD-infused beverages in Canada. And just last month, Aphria Inc. (NASDAQ: APHA) (TSX: APHA) announced the expansion of its 510 Vape offering across its award-winning adult-use brand portfolio. Curaleaf Holdings Inc. (OTC: CURLF) (CSE: CURA) recently launched its Select Nano Gummies in California and its line of Select Elite Live cartridges in Nevada.
- Projected trillion-dollar market presents compelling opportunity for companies prepared in the space.
- With already-established high standards in place, WTER guarantees that its A88CBD products are unmatched.
- The company just added five category-leading items to its A88CBD line, the perfect complement to its existing product lineup.
A Compelling Opportunity
In its report, Lido Consulting noted the following: “Pause to consider . . . a $1 trillion market in eight years while currently there is not a single company in the space that generates anywhere close to $500 million in revenue. That fragmentation, and the wholly unique phenomenon that a black market with an existing — and massive — consumer and patient base is transitioning to a regulated market, is what makes cannabis such a compelling opportunity.”
The already-high demand has only increased in the past year, with the COVID-19 epidemic sparling stronger online sales. In fact, a recent ASD Market Week article reported that every dollar spent on email marketing in the CBD industry brought in in almost $40 in revenue. That aligns with Brightfield Group research indicating that roughly one-third of CBD consumers surveyed plan to buy from online retailers rather than in-store during the pandemic, while nearly 50% plan to stock up on supplies if it looks like there will be a shortage.
Clearly, the sector offers opportunity for smart companies to offer a comprehensive line of CBD-infused and topical products — and emerge as a trusted brand. Who better to rise to the challenge than an already recognized beverage leader that has clearly established its ability to deliver on consumer needs and market opportunities?
Meeting Rigorous Requirements
The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) has worked hard to build a national reputation as a well-respected beverage brand, and the transition to becoming a similar presence in the CBD space has been seamless. With already-established high standards in place, WTER guarantees that its A88CBD products are formulated in GFM facilities; use the highest-quality, lab-tested CBD from a trusted source; and follow rigorous quality control measures to establish consistency.
These rigorous requirements will become even more essential as CBD becomes more mainstream, attracting a new products and brands to the space. Major players are eager to to add quality CBD products to their offerings, but these distributors have strict requirements. Smaller cannabis producers and brands with limited resources may be unable to produce products that meet those demands, but The Alkaline Water Company is already doing so.
As a trusted brand, WTER and its leading A88CBD brand provide exactly what retailers are demanding: superior quality topicals, oils, capsules, tinctures and gummies.
Capturing Share in $20-Billion Market
The Alkaline Water Company is clearly committed to its best-in-class A88CBD line; the company just launched five category-leading items. “These products, which include our delicious lemon-lime CBD water, vegan gummies, zero-calorie powder packs, all-natural bath bombs and cruelty-free deep relief cream, complement our existing product lineup,” said WTER president and CEO Richard A. Wright. “Our robust product lineup effectively positions us to capture share in the estimated $20 billion-plus, hemp-derived consumer products market.”
Focused on capturing as much of the growing market as possible, WTER is committed to grow both its online and in-store presence. A88CBD products are currently available in approximately 400 retail locations, including Elevated Wellness CBD, CBD Emporium, Alchemist Kitchen, Pure CBD, and select Vitamin Plus locations. Online, A88CBD products can be found on WTER’s direct-to-consumer e-commerce site at www.A88CBD.com the products are also available at Amazon, CBD.co, healwithnature.com and DirectCBDOnline.com
Developing both a vibrant online presence and robust retail locations is a priority for WTER as it works to increasing sales in the CBD space. With that in mind, Wright explained that the company is planning to continue to grow its online presence through unique digital marketing strategies and leverage its existing brick-and-mortar footprint for its A88CBD portfolio of products.
“We are in active discussions with over 9,000 retail locations to take on our products over the coming 90 days,” he said during the Q2 financial webcast. “With an in-demand portfolio of offerings, a strong partner network, and an established retail base, we are taking aggressive actions to capture share in the large and growing retail trades we currently serve and greenfield opportunities in the CBD and hospitality and foodservice arena. Additionally, our e-commerce sites continue to exceed our expectations and provide another growth area driven by shifting consumer behaviors. We also expect the multi-year health and wellness trend to accelerate coming out of the COVID pandemic and anticipate our lifestyle brands to benefit due to our sales and marketing efforts made this year.”
A Strong Candidate Fills Unique Niche
WTER’s impressive A88CBD product line is only one piece of The Alkaline Water Company’s strategic business puzzle. The company’s flagship product, Alkaline88(R), is one of the strongest performers in the beverage world, and the company continues to report record sales. “Our family of brands — Alkaline88, A88 Infused and A88CBD Infused — include a growing portfolio of products that are in demand and resonate with consumers,” Wright said.
A recent “Proactive Investor” article observed that “well-financed suitors may well be interested in the Alkaline Water Company given its unique niche. After all, a Neilson report ranked Alkaline88 as ‘one of the fastest growing’ value-added waters in 2019. It also noted that the company has built a ‘national retail footprint’ and extended its lifestyle brands into other consumer packaged goods categories.”
WTER’s stability and commitment to quality, along with its distinctive variable-cost business model and strong portfolio, make the company a strong prospect for major players in the beverage or cannabis space that are may be looking to strengthen their position in these key sectors.
Evaluating the Opportunities
With a trillion-dollar industry projection as a backdrop, it’s no wonder that other companies besides WTER are also evaluating the opportunities.
Tilray Inc.’s (NASDAQ: TLRY) new High Park portfolio additions for Canada in 2020 include edibles, confectionery goods, CBD beverages and more, expanding High Park’s existing broad-based portfolio of brands and products. The additions feature new confectionery brand Chowie Wowie(TM), new wellness brand Rmdy(TM), and new beverage brand Everie, developed by Fluent. In addition, the line brings U.S. brands Marley Natural(TM) and Goodship(TM) to the Canadian market. High Park’s team of brand leaders and R&D experts have worked rigorously to deliver to consumers best-in-class cannabis products that meet the highest standards of safety and quality as required by Health Canada.
Anheuser-Busch InBev SA (NYSE: BUD) has announced a joint venture with Tilray to commercialize non-alcohol, CBD-infused beverages in Canada once regulations allow. The joint venture will operate under the Fluent Beverage Company. AB InBev is participating in the partnership through its subsidiary Labatt Breweries of Canada, one of the country’s founding businesses and its leading brewer. Tilray is participating through its Canadian adult-use cannabis subsidiary High Park Company.
Aphria Inc.’s (NASDAQ: APHA) (TSX: APHA) expansion of its 510 Vape offering strengthens the company’s commitment to inspire and empower the worldwide community to live its best life. Each Aphria vape is designed with a unique offering to meet the demands of a diverse consumer segment. “Since day one we have been committed to strategically developing an award-winning brand portfolio that resonates with Canadians, provides exceptional patient and consumer experiences, and competes against the illicit market,” said Aphria CEO Irwin D. Simon. “We believe the strength of our brands remain unmatched in the industry and are excited to expand 510 vapes across our brand portfolio, including Broken Coast’s first cannabis 2.0 product.”
Curaleaf Holdings Inc. (OTC: CURLF) (CSE: CURA) is continuing its Western expansion of Select brand products. With the launch of its gummies in California and cartridges in Nevada, Curaleaf now offers products in 12 states. “The latest product expansion of Select in California and Nevada speaks to Cureleaf’s commitment to providing both medical patients and adult-use customers with accessibility to innovative, high-quality cannabis products,” said Curaleaf president Joe Bayern. “We are thrilled to bring Select’s scientifically formulated Nano Gummies and Elite Live to both states as we expand our portfolio and provide entry points for new consumers.”
The wave of acceptance for cannabis, and specifically CBD, isn’t likely to ebb, as a growing number of consumers look for superior products that provide life-changing benefits. Companies leading the way in the space will only benefit as the trillion-dollar mark grows closer.
For more information about The Alkaline Water Company, please visit The Alkaline Water Company.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate PCSA with a Speculative Buy rating as we consider the two leading assets in PCSA’s pipeline portfolio as most promising and with potential value. Eniluracil probably can reduce adverse events and improve efficacy of 5-FU/capecitabine that are standard-of-care for multiple cancer indications. Another asset, deuterated pentoxifylline, may help patients with ulcerative necrobiosis lipoidica, a skin disorder with no FDA-approved agents, to heal the ulcers in an expedient way. While we keep our current PoS at 20%, as PCSA moves forward in clinical development the value of the company should grow accordingly, in our opinion.”
To view the full report, visit: https://ibn.fm/9GWkG
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Financial numbers show revenues stay level, gross margins up and operations expenses down.
- Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery.
- POAI subsidiaries all showing progress, growth in key areas.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its Q3 2020 financial report along with an update of company accomplishments and achievements (https://ibn.fm/HCpQM). In the report, POAI CEO Dr. Carl Schwartz noted milestones for each of the company’s subsidiaries: Helomics, TumorGenesis, Soluble Biotech and Skyline Medical.
“Our operating cash improved over the first nine months of 2020 as a result of an improvement in operating expenses, if the non-cash expense for goodwill impairment is excluded, continued new sales of our STREAMWAY Systems, which provide an annuity-like revenue stream from ongoing sales of disposables, and proceeds from equity offerings, indicating investor confidence in our emerging precision medicine business,” said Schwartz. “Concurrently, we are taking the necessary steps to manage our balance sheet, including reducing our accounts payable and reducing our derivative liability by amending a settlement provision for certain outstanding warrants.
“Management continues to focus the majority of its resources on the company’s primary mission of applying artificial intelligence to precision medicine and to drug discovery,” Schwartz continued. “Our approach and the mediums used to replace rats and mice in preliminary cancer studies are working in three of our operating subsidiaries, Helomics, TumorGenesis and Soluble Biotech.”
In the report, Schwartz noted the following company milestones:
- Signed first contract with a pharmaceutical company for protein expression, solubility studies
- Completed asset purchase of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company
- Sold 15 STREAMWAY(R) systems
In addition, POAI reported its Q3 revenues — $0.5 million — were level with the same quarter last year; revenues were primarily driven by sales of Predictive Oncology’s proprietary STREAMWAY product line. In addition, gross margin was 64% in the third quarter of 2020 compared with 60% in Q3 2019, general and administrative expenses declined 15% to $2.2 million in Q3 2020, and operations expenses slightly decreased in the same period due to lower costs related to staff, including share-based compensation.
Regarding each of POAI’s subsidiaries, Schwartz made the following comments:
- Helomics: “We are making steady progress in our Helomics division with the launch of a restructured clinical test offering to clinicians for ovarian cancer. Our project with UPMC-Magee Womens Hospital, analyzing the genomic and drug response profiles of women with ovarian cancer to build predictive models’ terms of therapy response, is close to completion. We are also in discussions with several pharmaceutical companies about partnerships that will monetize our efforts.”
- Soluble Biotech: “We signed our first contract with a pharmaceutical company for protein expression and solubility studies. Importantly, this win validates our investment in state-of-the-art lab equipment and expanded facilities. We are working judiciously to secure additional contracts with other biotechnology and pharmaceutical companies.”
- TumorGenesis: “We introduced our Ovarian Cell Line Media at the BIO-Europe Digital Conference where numerous researchers learned from us how they can isolate and successfully culture ovarian cancer cells that previously could not be cultured. Cornell University (Weill) Medical School and TumorGenesis are collaborating to help identify the best culture media for the studying of mutations that increase the risk of ovarian, breast and other types of cancers.”
- Skyline Medical: “[This] division continues to be self-sustaining, from an operating cash perspective, as sales of new waste fluid management systems and recurring sales of disposables to support those systems more than cover the operating expenses and capital needs of this segment of our business. Importantly, sustaining and even modestly growing this division provides us with cash we need as we accelerate the precision medicine components of our business.”
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE) is a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc. The merger is optimally timed as more and more regulations aim to require and encourage adoption of purely electric automobiles as a replacement to conventional combustion engine-powered cars. A recent article discussing the company’s positioning reads, “Net Element and Mullen Technologies have revealed plans to begin their foray into the U.S. electric vehicle market through their partnership with Chinese EVET manufacturer, Qiantu Motors, with the aim of marketing and selling the latter company’s vehicles in the U.S. The joint-venture’s first product will be the K50 Dragonfly — an all-electric, two-seat, carbon-fiber-bodied sports car that can go from 0-100 km/hr in 4.6 seconds (faster than a Porsche Boxster) and which is set to begin deliveries from 2Q2021 onwards.”
To view the full article, visit https://ibn.fm/C1kqJ
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). The contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visitwww.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- Net Element plans to radically transform its business model following completion of merger with Mullen Technologies, converting into pure-play EV manufacturer
- Electric vehicles are set to account for 3% of global vehicle sales in 2020
- Governments have increasingly pushed for electric vehicle adoption as key pillar underpinning environmental objectives; the UK just announced ban on sale of fossil-fuel powered cars by 2030
- NETE CEO Oleg Firer recently elaborated on challenges of entrepreneurship, role of diplomacy within modern corporate management
Net Element (NASDAQ: NETE) presents its stakeholders with a unique business proposition: Within its role as a global financial technology and value-added solutions group, Net Element provides its customers with electronic payments solutions spanning across point-of-sale, e-commerce and mobile devices, both in the United States and in selected emerging markets. It is under this very model that the company has seen its fortunes rise exponentially, with revenues climbing from $0 in 2013 to $65 million as of 2019.
Under the leadership of CEO Oleg Firer, a veteran entrepreneur and corporate turn-around specialist, Net Element has recently sought to radically transform its business model, with plans to jettison its long-standing payments business in favor of converting into a pure-play electric vehicle (“EV”) manufacturer (https://ibn.fm/kdqCv).
On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately held Mullen Technologies Inc., a Southern California-based electric vehicle company. The transaction, which will be in the form of a stock-for-stock reverse merger where Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company, will mark Net Element’s entry into one of the fastest-growing sectors within the global economy (https://ibn.fm/dYUea).
According to the International Energy Agency, sales of electric vehicles topped 2.1 million units globally in 2019, boosting the global stock to 7.2 million electric vehicles. The sector has evidenced a precipitous surge in growth, with electric vehicles – which accounted for 2.6% of global car sales and about 1% of the global automotive stock in 2020—registering a 40% year-on-year increase in sales last year; meanwhile, electric vehicles sales are anticipated to continue growing relative to those of their internal combustion engine-powered peers, accounting for approximately 3% of global car sales in 2020.
In addition to their growing popularity among automobile purchasers, electric vehicles have gained in prominence given that they represent a key technology to be used in high-profile global initiatives: the reduction of air pollution in densely populated areas and in the assistance of achieving greenhouse gas emissions reduction objectives. To date, 17 countries have announced 100% zero-emission vehicle targets, with the UK recently announcing a domestic ban on the sale of fossil fuel-powered vehicles by 2030 (https://ibn.fm/Ne5dU).
While Net Element’s segue into the electric vehicles space demonstrates remarkable foresight given the growth prospects attributed to the sector, it does not come without its own inherent challenges – ensuring corporate management ‘buy-in’ may be just as critical as a sector’s long-term potential, according to CEO Oleg Firer.
“Being a chief executive in business is very similar to being a diplomat,” Firer noted. “Managing a business in today’s environment requires constant negotiations at the executive levels and diplomatic approach to mid-management. One of my favorite diplomatic approaches to management is an ability to promote and seed an idea or a solution within, where your colleagues begin to believe in it as much as they begin present and solicit this idea or solutions rest of the group.”
Given Firer’s stellar track-record at the helm of various companies – which has included being awarded Inc Magazine’s prize as the United States’ fastest growing private sector company in 2012, the future looks bright for Net Element as it prepares to take on new challenges amidst the company’s planned foray into the world of electric vehicles.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
iClick Interactive (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, and its board of directors has announced a share repurchase program. The program allows ICLK to purchase its own ADSs with an aggregate value of up to $15 million during the period of Dec. 30, 2020, to Dec. 31, 2021. The company intends to fund the repurchase using existing cash balance funds, which include monies generated from operations. iClick expects to effect the proposed program in three ways: on the open market at prevailing market prices, in negotiated transactions off the market, and in other permissible ways that are in compliance with applicable requirements. The announcement notes that the company is not obligated to acquire any particular number of ADSs; the share repurchase program may also be suspended, terminated or extended at any time. “This share repurchase program demonstrates our continued confidence in our long-term business growth and successful transformation towards an Integrated Enterprise and Marketing Cloud Platform,” said iClick co-founder and CEO Jian “T.J.” Tang in the press release. “We are committed to creating shareholder value, and believe that our business strategy and execution ability will continue to drive the long-term growth of the firm.”
To view the full press release, visit http://ibn.fm/F94q9
About iClick Interactive Asia Group Limited
iClick Interactive is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, the company’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in 10 locations worldwide including Asia and Europe. For more information about the company, please visit www.iClick.com.<
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
With more companies and countries going green, the demand for some metals and other renewable energies is bound to increase. This makes mining an important feature in a low-carbon future. Some of the minerals whose demand may grow include rare earth elements, cobalt and nickel.
The executive director of Mining Industry ML Ed Moriarity explains that the demand for both cobalt and nickel is expected to increase by more than 1,000% by the year 2050. Both cobalt and nickel are used in batteries of electric vehicles.
The battery industry is also forecasted to grow in the next decade to $90 billion from $23 billion. This increase will mainly be caused by the growth in adoption of electric vehicles (EVs). The UK is also planning to ban the sale of diesel and petrol cars by the year 2030, which will help further boost the industry.
Tesla founder Elon Musk recently announced to investors that the company was willing to award a huge contract to any firm that could mine nickel in a way that was both environmentally sensitive and efficient. He added that the contract would last for a long time, as Tesla needs a mining company that can meet the EV firm’s demands, which are expected to increase as more people shift to electric vehicles.
This may be good news for Vale, the operator of Voisey’s Bay, which has what we may call ethical nickel deposits. In 2018, Vale announced that it would be extending its Labrador mine’s life, moving its operations further underground. While the pandemic may have interfered with the company’s plans, Vale did announce recently that the two underground mines are 55% complete. One of the mines is set to begin production in summer 2022 and another in spring 2021.
Once this expansion is complete, the operational costs of the mine will double, and its capital costs will become four times as much. However, to discover new mining sites that hold deposits of the minerals, mineral mapping needs to be conducted. This may take some time, as there’s a lot that goes into exploration work. Voisey’s Bay, for example, was discovered in 1993 but didn’t begin production until almost 12 years later.
Despite not being in commercial production at the moment, Southern Labrador and its rare earth element deposits, which has metals such as cobalt and nickel, is going to be in high demand as vehicle electrification grows. These metals are used in various gadgets, including smartphones, computers and TV screens.
The United States also has its fair share of mining firms excelling at what they do. An example is Energy Fuels Inc. (TSX: EFR) (NYSE American: UUUU). The company’s success at extracting vanadium and uranium has allowed it to branch out into the production of rare earth elements.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
LAKEWOOD, Colo. , Dec. 10, 2020 – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) , a leading producer of critical minerals in the United States , is pleased to announce that the Company’s President and CEO Mark S. Chalmers will be presenting live at the 13 th Annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 11:40 AM (EST) .
Mr. Chalmers will provide an update on Energy Fuels’ various critical mineral initiatives, with particular emphasis on the Company’s progress on rare earth elements.
Register Here: ve.mysequire.com/
The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.
“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji , Funder of LD, now a wholly owned subsidiary of SRAX, Inc.
The Main Event will take place on December 14 th and 15 th , exclusively on the Sequire Virtual Events platform.
View Energy Fuels’ profile here: http://www.ldmicro.com/profile/uuuu
Profiles powered by LD Micro
About Energy Fuels : Energy Fuels is the leading U.S.-based uranium mining company, supplying U 3 O 8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and it is evaluating the potential to produce rare earth elements. Its corporate offices are near Denver, Colorado , and all of its assets and employees are in the United States . Energy Fuels holds three of America’s key uranium production centers – the White Mesa Mill in Utah , the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming , and the Alta Mesa ISR Project in Texas . The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U 3 O 8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U 3 O 8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U 3 O 8 per year. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com .
About LD Micro/SEQUIRE : LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com . The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe. In September 2020 , LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire , companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com .
Cautionary Note Regarding Forward-Looking Statements: This news release contains certain “Forward-Looking Information” and “Forward-Looking Statements” within the meaning of applicable United States and Canadian securities legislation, which may include, but are not limited to, statements with respect to any expectations regarding: uranium production, uranium and vanadium inventories and progress on rare earth elements . Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects,” “does not expect,” “is expected,” “is likely,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “does not anticipate,” or “believes,” or variations of such words and phrases, or state that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” “be achieved” or “have the potential to.” All statements herein, other than statements of historical fact, are considered to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance of or achievements of the Company to be materially different from any future results, performance, or achievements, express or implied, by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: any expectations regarding uranium production, uranium and vanadium inventories and progress on rare earth elements; and the other factors described under the caption “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K, which is available for review on EDGAR at www.sec.gov/edgar.shtml , on SEDAR at www.sedar.com , and on the Company’s website at www.energyfuels.com . Forward-looking statements contained herein are made as of the date of this news release, and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or as a result of changes in management’s estimates or opinions, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update the information in this communication, except as otherwise required by law.
The mental health treatments being used around the world sometimes seem to be doing more harm than good to their consumers, with patients often becoming either addicted to their treatments or treatment resistant. Atai Life Sciences cofounder Florian Brand states that only 50% of individuals respond to selective serotonin reuptake inhibitors, which is the most common depression and anxiety treatment. In addition, this approach can take up to three months for an individual to notice any changes in their symptoms, and individuals have a 33% probability of their bodies resisting the treatment.
Backed by its founders, Atai Life Sciences believes that psychedelics may help. Currently, the firm is developing mental health treatment drugs that include psilocybin, MDMA and ketamine. The company, which was launched in 2018, announced last month that it had raised $125 million in new funding from investors such as Peter Thiel, PayPal founder and Facebook investor.
Brand explains that the company’s aim is to fast track mental health innovation in a responsible way. He adds that his interest in the psychedelic treatments stem from personal mental health experiences. He explains that he suffered from severe anxiety and was treated with psychotherapy but adds that, while it may have worked for him, many others do not respond to the treatment options available.
The firm owns 10 other companies that each work on a different compound designed to help treat mental health conditions. Compass Pathways, one of the companies operating on this decentralized strategy for drug development, is developing a psilocybin treatment. This psychedelic substance is effective in unlocking an individual’s trauma that resulted in a mental health issue, thus allowing the cause to be explored further in therapy.
Another company is working on a drug that is akin to esketamine, which is currently used to manage depression. The drug is arketamine, which can be given at home as it gives rise to less of a hallucinogenic effect.
One of the company’s other firms is working with ibogaine, which has the potential to be used in the treatment of an addiction to opioid. The psychoactive compound occurs naturally in the root bark of Tabernanthe iboga, an African shrub.
Brand also explains that Atai is focused on developing drugs that are tailored to treat mental health conditions differently in different individuals. The company is currently developing tracking biomarkers, which will help indicate the type of help that a patient requires.
Additionally, the company is working on making its drugs more affordable. The reason behind this is because a majority of people with depression cannot afford treatments that are out of pocket.
Atai isn’t the only company in the psychedelics sector though. Other players are also taking bold steps in this industry. For example, Cybin Inc. (NEO: CYBN) is hard at work developing pharmaceutical products from psychedelic substances, and the company also has an interest in the functional mushroom segment.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million) in an all-stock transaction. The transaction is subject to the satisfaction or waiver of customary conditions, including receipt of all applicable regulatory and NEO Exchange Inc. approvals. “We are thrilled to join forces with Adelia, as we see this transaction as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focus on creating novel therapeutics, including novel delivery methods and innovative therapeutic regimens can support our goal of creating therapies that result in faster onset of action, smoother pharmacokinetic profiles, shorter treatment durations, and reduced side effects,” said Cybin CEO Doug Drysdale. “Leveraging Adelia’s expertise across multiple molecules and multiple indications could potentially allow Cybin to extend its reach and capability to address gaps across a larger domain.”
To view the full press release, visit http://ibn.fm/poDlp
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
People work out for different reasons. Some want to keep fit and healthy whiles others have aesthetic in mind; still others may be training for an upcoming competition or event. Doctors recommend working out to maintain good health, advising that we make it part of our daily routines. A good workout plan should factor in the risk of injury and how to avoid it. Injuries only impede your progress. To avoid this, here are some ways you can avoid injuries whe working out.
Stretch and do warm-up exercises before you begin.
Taking a few minutes to warm up helps your muscles loosen up before you commence your workout. Stiff muscles are susceptible to injury. You can choose from various warm-up exercises. However, it’s recommended that you do warm-up exercises that will help loosen the muscles in the part of the body that your workout is focused on. Some common warm-up exercises include leg and arm lifts, pushups and walking.
Start your workout slow
If you haven’t exercised in a while, you should start with slow workouts. Muscles need time to get used to the stress that comes with working out. So you should avoid getting into working out again too fast with intense workouts. Some soreness in your muscles after exercise is completely normal, but be aware of the danger of overworking your muscles when working out. If that’s the case, you will need to slow down.
Work on being more flexible
Being more physically flexible is good for your body. Improving your body’s flexibility also prevents you from injuring your muscles when working out. Additionally, flexibility helps your muscles withstand more physical stress. Activities such as dynamic stretches and yoga will help steer clear of muscle underdevelopment and weakness. Muscles that are underdeveloped or weak are prone to tears and pulls. Enhancing your flexibility will make your muscles stronger.
Give yourself time to recover
When working out, you should ensure that your body has time to rest. Some people believe that rest time in between workouts only impedes your progress, but that isn’t true. Taking time to let your body recover helps ensure that you do not overwork your body. When working out, your muscles are engaged. Recovery time gives your body time to repair. Working out every day with no days off in between workouts will result in your muscles breaking down and being more prone to injury.
Lots of firms are busy at work ensuring that people enjoy better health. For example, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is notable among biotech companies because of its focus on searching for treatments targeting cancers that attack the brain impact the central nervous system.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points.
- Berubicin IND accepted for review by FDA
- Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better
- Adult Phase 2 trials to commence in Q1 2021
The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”) application to the FDA for Berubicin. The broadcast also detailed the company’s plans to commence adult Phase 2 trials of the drug during the first quarter of 2021.
Since review of the IND application has not been completed, it may seem a little strange that CNSP is already looking ahead to Phase 2 clinical trials. However, Berubicin has already been the subject of Phase 1 trials, which are focused on finding the safest effective dose of a drug. In 2006, Reata Pharmaceuticals, a clinical-stage biopharmaceutical company conducted clinical trials that have had quite encouraging results.
Fortuitously, 11 of the 25 cancer patients who were treated with Berubicin and were available for evaluation in those initial clinical trials “experienced a statistically significant improvement in progression-free survival” (https://ibn.fm/OgkZB). Moreover, “one patient experienced a durable complete response, which is defined by the National Cancer Institute as the disappearance of all signs of cancer in response to treatment.” This means that that patient has suffered no recurrence and has remained cancer free for more than 13 years. Two other patients saw reductions in tumor size of up to 80%.
Berubicin has been developed to treat glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. The drug is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs. Anthracyclines are also effective against more types of cancer than any other class of chemotherapeutic agents. They are designed to utilize natural processes to induce deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. In effect, Berubicin prevents cancerous cells from replicating.
The Phase 2 clinical trials will be conducted in conjunction with WPD Pharmaceuticals Inc. Additionally, there are plans afoot for WPD Pharmaceuticals to commence a first-ever Phase 1 trial with children in the near future. This pediatric trial will be conducted at Children’s Memorial Health Institute, the largest pediatric hospital in Poland.
CNSP is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. In June 2020, the company hired U.S.-based Pharmaceutics International Inc. (“Pii”) and Italian BSP Pharmaceuticals S.p.A. (“BSP”) to handle production of the drug. Synthesis of the Berubicin Active Pharmaceutical Ingredient (“API”) had already been completed, and the API has been delivered to the two manufacturing entities; both have now prepared an injectable form of Berubicin to be used in the clinical trials.
With the production process fully underway, the company is a step closer to getting its IND approved by the FDA. With this dual-track approach to manufacturing, the company reduces the risk of failing to meet its clinical timeline. Moreover, situating production in Europe as well as the United States provides localized availability of Berubicin for the upcoming Phase 1 pediatric and Phase 2 adult studies in Poland and the U.S. Phase 2 trials.
Glioblastoma is one of the most aggressive primary brain cancers in adults, with approximately 13,000 new patients diagnosed each year in the U.S.—the highest diagnosis rate of all malignant brain tumors. An effective way of fighting this pernicious affliction is sorely needed.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
It may be conceivable that everyone has a phobia; some are small while others can be crippling. Remember Ron Weasley and his phobia of spiders? While some people are only slightly fazed by their phobias, which are defined as irrational fears, others are significantly impacted by them, going as far as to avoid doing certain things or going to specific places because of them.
According to the National Institute of Mental Health, nearly 19 million individuals in the United States have a phobia, making phobias a common mental disorder in the nation. Some evidence indicates that the use of marijuana could benefit those struggling with these intense fears.
Evidence gathered in the last six years shows that cannabis compounds, or cannabis in general, may be used to help individuals with specific phobias. A study conducted by the University of Michigan discovered that THC, which is a cannabis compound, may alleviate the anxiety of patients with phobia. In the study, which was reported in the “Neuropsychology” journal, researchers cited the discovery that THC helped some patients with phobias to not only work through their fears but also overcome them.
The study involved nearly 30 participants and utilized a skin conductance response recording and a simultaneous Pavlovian fear extinction paradigm during the study. The researchers dosed patients using dronabinol, which is a synthetic version of THC. They noted that over time individuals who were under the influence of THC exhibited less fear.
Study results provided evidence suggesting that extinction learning of phobias through pharmacological enhancement was achievable in humans through the use of cannabinoid system modulators. The authors of the study concluded that this called for more clinical research and testing to be conducted.
A separate 2017 study demonstrated that CBD, another cannabis compound may possess therapeutic benefits that help deal with certain phobias. The study, published in the “Frontiers of Pharmacology,” was led by University of Birmingham’s Chenchen Song. The study used rats as tests subjects and administered 10mg CBD injections to the rats.
Researchers observed that these injections decreased the fear memory in the rodents. While rats aren’t privy to human fears such as flying or heights, Song notes that the marijuana component they administered made the rodents less afraid of being eaten alive by predators. CBD has also proven effective in helping treat PTSD.
From the above, it is feasible that individuals who have phobias may use medical cannabis to help alleviate their fears. Phobias are currently managed by using tranquilizers and antidepressants, which may do more harm than good.
Many cannabis-related entities have opted to focus on lifestyle products. For example, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) has become famous for its trace mineral-rich alkaline water as well as its topicals and edibles infused with cannabidiol.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
NEW YORK, Dec. 09, 2020 — via InvestorWire — The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
To view the full publication, “National Brands Vie for CBD Dominance,” please visit: https://nnw.fm/WYoJD
On election day this year, four more states voted to legalize the recreational use of cannabis, bringing the total of states that now allow recreational cannabis use to 15. This growing acceptance of cannabis, and more specifically CBD, which is now legal in all 50 states, has sparked an explosion of new CBD-infused products and brands within the consumer packaged goods (CPG) space. Estimates about how large the legalized cannabis market may grow vary widely, but a Lido Consulting report notes that the total addressable cannabis market (TAM) could potentially hit $1 trillion in global economic impact by 2027.
Seeing almost unlimited potential, companies are rushing to take advantage of the massive opportunity. Continuing its aggressive growth strategy, The Alkaline Water Company Inc. (NASDAQ: WTER)(CSE: WTER) entered the CBD space with the launch of its A88CBD(TM) brand. Already nationally recognized for its premium bottled water and flavor-infused water, Alkaline Water now features a full line of CBD-infused and topical products. After posting record sales earlier this year, this strategic push into the lucrative CBD market could propel the company to new records.
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com .
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://nnw.fm/WTER
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.
NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced its entry into a memorandum of understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to support specific near-term opportunities with world renown resorts, national tourism boards, major airlines, airports, cruise ships, and ports. On Oct. 19, 2020, Loop and Empower Clinics (CSE: CBDT) (OTC: EPWCF) (FRA: 8EC) announced a partnership that created the first-ever COVID-19 “Travel Bubble,” combining each company’s respective expertise in venue tracing and testing, each of which has made significant technological advancements and milestones in the interim. “This partnership is a very important and powerful next step to accelerate Loop’s potential growth. With the company’s recent launch of its first live venue events, with the whole world watching, including world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class,” said Loop Insights CEO Rob Anson. “By adding the direct integration with Empower’s diverse testing capabilities and SimpliFlying’s network of large-scale customer projects, we have now commenced significant discussions surrounding travel bubble opportunities with some of North America’s largest airlines, resort operators, venues, and hospitality groups globally. We anticipate this new revenue stream may be significant for the company as we progress these opportunities in 2021.”
To view the full press release, visit https://ibn.fm/1alw7
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network. For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- SRAX to host 13th Annual LD Micro Main Event on December 14-15, 2020 via its SRAX Virtual Events SaaS platform
- Conference will feature over 250 company presentations, interviews include Shaquille O’Neal and 2020 presidential candidate Brock Pierce
- 2 million+ small-cap investors invited from SRAX’s active investor base
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, will be hosting the 13th Annual LD Micro Main Event on December 14-15, 2020 via its Sequire Virtual Events SaaS platform. Over 250 companies are scheduled to present to a potential audience of over 2 million invited guests. Attendees will have exclusive access to interviews with Shaquille O’Neal and 2020 presidential candidate Brock Pierce along with other influential panelists across the small-cap space.
Since being acquired by SRAX, LD Micro – already a leader in small- and micro-cap conferences – has gained access to the largest active base of micro-cap investors in the world at over 2 million and counting. Since its inception in 2006, LD Micro has grown from a newsletter into a prominent portal that provides exclusive intraday information covering North American stocks with market capitalizations between $50 million and $300 million. The LD Micro Main event this year is set to be one of the company’s most ambitious endeavors in its history, set to bring together millions of potential investors with companies in the flourishing micro-cap space.
“I think the Main Event will be the first virtual conference this year that is engaging instead of repetitive,” said LD Micro Founder and CEO Chris Lahiji (https://ibn.fm/bAOws). “There have been too many 20-minute PowerPoints, and investors have lost the desire to watch one more of the same thing. We intend to showcase something different.”
Besides its all-new presentation format, the conference will be presented on Sequire, SRAX’s SaaS platform that leverages data analytics for public companies. Tailored to the investment industry, Sequire helps public companies unlock valuable data and insights that can be used to create and activate marketing campaigns in order to attract new investors and engage existing shareholders.
“With the launch of this virtual conference, we are one step closer to our mission of creating the most comprehensive platform for issuers,” said SRAX Founder and CEO Christopher Miglino. “We believe this conference will be a success for both the investors and the issuers in the Sequire community, and we look forward to the expansion of the LD Micro audience.”
Investor relations in recent years have undergone a rapid transformation with the advent of data-based platforms that allow public companies to track their investors’ behaviors and trends. The movement is projected to continue at a rapid pace, positioning SRAX favorably in the investor relations industry, set to radically transform from innovations in the collection and application of investor data.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.
Genprex will present at the Benzinga Global Small Cap Conference on December 8, 2020 at 2:30 p.m. EST. Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors.
For more information, visit the company’s website at www.genprex.com.
For further details on Benzinga’s Global Small Cap Conference and other events, visit https://www.benzinga.com/events/small-cap/
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured session.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Scientists at the Georgia State University Institute for Biomedical Sciences have found that the MK-4482/EIDD-2801 antiviral drug, which was developed to treat the SARS-CoV-2 infection, completely stops transmission of the virus in 24 hours.
The researchers, led by distinguished Georgia State University professor Dr. Richard Plemper, initially discovered that the drug was strong against influenza viruses. Plemper explains that this was the first test for a drug that is orally available and that can stop the transmission of SARS-CoV-2. He adds that MK-4482/EIDD-2801 may be a game-changer.
Stopping the transmission of the SARS-CoV-2 virus on a wide scale until vaccination is available to the masses is key, as it allows authorities to manage the coronavirus while reducing the catastrophic consequences the pandemic may create.
As the drug can be ingested orally, treatment can commence early for the following benefits: to quickly avert any local outbreaks; to cut down the infectious phase, which will in turn relieve both the socioeconomic and emotional toll of patient isolation; and to slow down the progress of the deadly disease.
Plemper also explains that in the early stages of the study, the researchers noted that MK-4482/EIDD-2801 can be used to fight against many respiratory RNA viruses, adding that when used by mouth to treat infected animals, the drug decreased the number of viral particles that were shed, which decreased transmission. These attributes made the drug a strong coronavirus pharmacologic control candidate.
Plemper’s team reused the drug on a ferret model to observe the impact the drug had on stopping the virus from spreading. The study, which was published in “Nature Microbiology,” documents these findings in detail. The researchers initiated the MK-4482/EIDD-2801 treatment after the ferrets began to discharge the virus through their noses after they had been infected with the SARS-CoV-2 virus.
The co-lead author of the study, Dr. Robert Cox, states that the researchers believed ferrets to be a suitable transmission model because, while they mostly don’t develop the SARS-CoV-2 disease, they readily spread it. This bears a resemblance to how the virus is spread in young adults.
Another co-lead author of the study, Josef Wolf, a Plemper lab doctoral student, observed that no ferrets were infected with the virus when the researchers joined ferrets that were infected with the virus but had been treated with ferrets that did not have the virus. Translated to humans, this means that patients who have the coronavirus and are treated using this drug could become non-infectious within the first 24 hours after their treatment commenced. The drug is currently in its phase 2 and 3 of advanced clinical trials.
The SARS-CoV-2 virus isn’t the only health threat that we are currently confronted by. Cancer is another growing problem, which is keeping lots of firms hard at work. For instance, Predictive Oncology (NASDAQ: POAI) has devoted all its energies towards developing customized cancer treatments by tapping the powers of data analytics and AI.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per year. Predictive Oncology can save approximately $158,000 annually in state taxes by reincorporating in Nevada.
To view the full press release, visit: https://ibn.fm/wMinE
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative solutions for the worldwide life science and other industries, recently reported its third-quarter financial results and provided a business update, which included initial expectations for 2021 (https://ibn.fm/8PNFi). Among the updates, the Q3 2020 Form 10-Q financial report outlines measurable progress in three important areas: key operational and technical projects; revenue increases in the company’s products and services offerings; and important structuring improvements in the reduction of arduous, variable-rate convertible debt. A recent article discussing this reads, “Providing other updates and plans for 2021, the Form 10-Q report also mentioned that Pressure BioSciences is on track to launch its innovative BaroShear K45 Nanoemulsification System by mid-2021. Purchase orders for the 12 BaroShear K45 systems the company intends to manufacture in early 2021 have already been received ahead of the planned mid-2021 commercial release. This novel and proprietary system, based on the company’s Ultra Shear Technology(TM) (‘UST’) patented platform, is designed to revolutionize the processing of immiscible liquid into water-soluble nanoemulsions.”
To view the full article, visit https://ibn.fm/rmySv
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life science and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”
To view the full press release, visit http://ibn.fm/Swa22
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health care platform, today announced the launch of Trxade Prime, a revolutionary service offered by the company’s Integra Pharma Solutions subsidiary. According to the update, Trxade Prime solves a historic problem for independent pharmacies suffering from an already complex prescription distribution process. The solution allows Trxade platform independent pharmacy members to process, consolidate and ship purchase orders placed directly with Trxade Suppliers via the Trxade Prime service. “The mission of Trxade, from its inception, has been to empower and encourage growth within the independent pharmacy community,” said Trxade Group CEO and Founder Suren Ajjarapu. “The development of Trxade Prime was the result of feedback from our significant pharmacy member base on ways to enhance purchasing efficiencies and cost savings. The overwhelming feedback Trxade received includes the difficulties pharmacies face meeting multiple supplier requirements on order minimums, individual invoicing with vastly varied payment terms and the lack of consolidated information with regard to tracking multiple orders with differing delivery dates, times and shipping costs.”
To view the full press release, visit http://ibn.fm/lvc9Y
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms: (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Delivery services have proliferated during the coronavirus pandemic as a result of the many restrictions imposed in a bid to contain the deadly virus. Marijuana delivery has not been left behind, with the substance becoming more accessible in many parts of the country. However, because this service is a little difficult to maneuver and new to the industry, there are a few things to consider when choosing a delivery service that works for you, while keeping laws on marijuana delivery in mind.
Determine if they accept debit/credit cards
While some states may limit marijuana sales to cash, delivery services where medical marijuana delivery is allowed may accept debit and credit cards. Additionally, you should inquire on the other payment methods they accept.
Check if the delivery service is compliant
All legal medical marijuana delivery services are required to follow local and state marijuana laws. If you plan on using any medical marijuana delivery service, you should ensure that the delivery service you will be using has its legal documentation in order. This will keep you from running into any legal trouble while also ensuring that you get your marijuana products from a creditable source.
To do this, you should look for the medical marijuana license for the delivery company. This is usually displayed in email communications and on websites.
See if the company’s services are local
Legal medical marijuana delivery services are mostly linked to local businesses, which either cater to a certain location or have a reputable name in the area. If a service is not local, they may omit that information, thereby providing a clue about their location.
Ask if your purchase is tax inclusive
Medical cannabis products are taxed, just like any other consumer product. If your delivery service doesn’t tax their products, you should tread carefully or terminate the use of their services, as they may not be complying with local restrictions and regulations.
You should also ask whether you require a medical cannabis card to place your order. This will allow you to seek delivery services that do, in fact, cater to medical cannabis cardholders, thus saving you time.
Identify the delivery time frame
You’ll want to find a medical marijuana delivery service that is convenient, provides you with a specific delivery time frame, and delivers your order on time. Additionally, the service should update you on the timeline and route of your order delivery and provide you with approximate delivery times. Beware of any service that delivers orders unusually late in the evening/night.
Excluding medicinal marijuana products, many firms are making products that are proving to be popular among consumers. One such entity is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). This Arizona-based company focuses on producing alkaline drinking water containing numerous trace minerals; WTER also recently added a line of CBD edibles and topicals.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
NetworkNewsWire Editorial Coverage: On election day this year, four more states voted to legalize the recreational use of cannabis, bringing the total of states that now allow recreational cannabis use to 15. This growing acceptance of cannabis, and more specifically CBD, which is now legal in all 50 states, has sparked an explosion of new CBD-infused products and brands within the consumer packaged goods (“CPG”) space. Estimates about how large the legalized cannabis market may grow vary widely, but a Lido Consulting report notes that the total addressable cannabis market (“TAM”) could potentially hit $1 trillion in global economic impact by 2027. Seeing almost unlimited potential, companies are rushing to take advantage of the massive opportunity. Continuing its aggressive growth strategy, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile) entered the CBD space with the launch of its A88CBD(TM) brand. Already nationally recognized for its premium bottled water and flavor-infused water, Alkaline Water now features a full line of CBD-infused and topical products. After posting record sales earlier this year, this strategic push into the lucrative CBD market could propel the company to new records. Also quick to see the opportunity, Constellation Brands Inc. (NYSE: STZ) recently exercised warrants to purchase additional shares of Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), increasing its stake in the Ontario cannabis producer to more than 38%. In a nod to the value of having CPG expertise, Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) has appointed Miguel Martin, an international CPG executive, as its chief commercial officer. And Charlotte’s Web Holdings Inc. (OTC: CWBHF) (TSX: CWEB) has announced a collaboration between its CW Labs science division and the University at Buffalo’s Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids.
- Growing acceptance of cannabis, specifically CBD, has sparked explosion of new CBD-infused products, brands within the consumer packaged goods (CPG) space.
- WTER’s A88CBD product line meets stringent requirements as CBD becomes more mainstream.
- Well-financed suitors may well be interested in The Alkaline Water Company given its unique niche strength, appeal.
A Massive Consumer Base
“Pause to consider,” the Lido Consulting article observed, “a $1 trillion market in eight years while currently there is not a single company in the space that generates anywhere close to $500 million in revenue. That fragmentation, and the wholly unique phenomenon that a black market with an existing — and massive — consumer and patient base is transitioning to a regulated market, is what makes cannabis such a compelling opportunity.”
That demand has only increased in the past year, with the COVID-19 epidemic fueling online sales. In fact, one study reported that every dollar spent on email marketing in the CBD industry resulted in almost $40 in revenue. And research by the Brightfield Group shows that roughly one-third of the CBD consumers surveyed indicated they are planning to buy from online retailers rather than in-store during the pandemic, while nearly 50 percent say they will stock up on supplies if they believe there is going to be a shortage.
The industry seems primed for a leading company to offer a comprehensive line of CBD-infused and topical products — and emerge as a trusted brand. Who better to step into the spotlight than an innovative company that has already firmly established its ability to quickly identify and deliver on consumer needs and market opportunities?
CBD Attracts New Wave of Entrants
Already a well-respected national beverage brand, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) is committed to building a similar reputation in the CBD sector. With those high standards in mind, WTER ensures all its A88CBD products are formulated in GFM facilities; use the highest-quality, lab-tested CBD from a trusted source; and follow rigorous quality control measures to establish consistency.
These stringent requirements are essential as CBD becomes more mainstream, attracting a new wave of entrants. Large national retailers are actively looking to add quality CBD products to their shelves, but these distributors have stringent requirements. Smaller cannabis producers and new brands with limited resources lack the resources to provide such high-quality products. However, their weakness is The Alkaline Water Company’s strength.
As a trusted brand, WTER and its best-in-class A88CBD brand offer precisely what retailers are looking for: superior quality topicals, oils, capsules, tinctures and gummies.
Capturing Share in Large, Growing Markets
The Alkaline Water Company is deeply committed to its A88CBD line, launching five category-leading items during Q2 FY 2021. “These products, which include our delicious lemon-lime CBD water, vegan gummies, zero-calorie powder packs, all-natural bath bombs and cruelty-free deep relief cream, complement our existing product lineup,” said WTER president and CEO Richard A. Wright. “Our robust product lineup effectively positions us to capture share in the estimated $20 billion-plus, hemp-derived consumer products market.”
Intent on capturing as much of the growing market as possible, WTER is strengthening both its online and in-store presence. A88CBD products are currently available on the company’s direct-to-consumer e-commerce site at www.A88CBD.com and in approximately 400 retail locations, including Elevated Wellness CBD, CBD Emporium, Alchemist Kitchen, Pure CBD, and select Vitamin Plus locations; the products are also available online at Amazon, CBD.co, healwithnature.com and DirectCBDOnline.com. Having both a vibrant online presence and robust retail locations is essential for companies committed to increasing sales in the CBD space. With that in mind, Wright also noted that the company is looking to continue to expand its online presence through unique digital marketing strategies and leverage its existing brick-and-mortar footprint for its A88CBD portfolio of products.
“We are in active discussions with over 9,000 retail locations to take on our products over the coming 90 days,” he said during the Q2 financial webcast. “With an in-demand portfolio of offerings, a strong partner network, and an established retail base, we are taking aggressive actions to capture share in the large and growing retail trades we currently serve and greenfield opportunities in the CBD and hospitality and foodservice arena. Additionally, our e-commerce sites continue to exceed our expectations and provide another growth area driven by shifting consumer behaviors. We also expect the multi-year health and wellness trend to accelerate coming out of the COVID pandemic and anticipate our lifestyle brands to benefit due to our sales and marketing efforts made this year.”
A Strong Candidate Fills Unique Niche
A88CBD is only a piece of The Alkaline Water Company’s strategic business approach. The company’s flagship product, Alkaline88(R), continues its strong performance in the beverage world, contributing to the company’s record sales reported in October. “Our family of brands — Alkaline88, A88 Infused and A88CBD Infused — include a growing portfolio of products that are in demand and resonate with consumers,” Wright said.
A recent Proactive Investor article noted that “well-financed suitors may well be interested in the Alkaline Water Company given its unique niche. After all, a Neilson report ranked Alkaline88 as ‘one of the fastest growing’ value-added waters in 2019. It also noted that [the company] has built a ‘national retail footprint’ and extended its lifestyle brands into other consumer packaged goods categories.”
WTER’s consistency and commitment to quality, along with its unique variable-cost business model and growing portfolio, certainly bode well for the company, making it a strong candidate for a savvy beverage or cannabis brand looking to strengthen its position in the growing sectors.
Evaluating, Seizing the Opportunities
With a trillion-dollar industry projection providing incentive, WTER isn’t the only CBD company to strategically evaluate — and seize — the opportunities.
Back in 2017, Constellation Brands Inc. (NYSE: STZ), a leading beverage alcohol company, signed an agreement to acquire a 9.9% minority stake in Canada-based Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED). The investment was consistent with Constellation Brands’ long-term strategy to identify, meet and stay ahead of evolving consumer trends and market dynamics, while maintaining focus on its core total beverage alcohol business. Constellation’s move earlier this year to significant increase that interest signifies the company’s recognition of possibilities within the industry.
“While global legalization of cannabis is still in its infancy, we continue to believe the long-term opportunity in this evolving market is substantial,” said Constellation Brands president and CEO Bill Newlands. “Canopy is best positioned to win in the emerging cannabis space.”
Aurora Cannabis Inc.’s (NYSE: ACB) (TSX: ACB) new chief commercial officer has deep, diverse experience in consumer packaged goods, highly regulated industries and the U.S. cannabinoid industry. “Miguel is a highly experienced executive with an exceptional track record of performance in a number of consumer products categories,” said Aurora executive chairman Michael Singer. “The Aurora Board and I firmly believe that under Miguel’s leadership, Aurora’s strategic direction going forward will be characterized by leading market performance, sustainable growth, profitability and value creation for shareholders.”
Charlotte’s Web Holdings Inc.’s (OTC: CWBHF) (TSX: CWEB) new scientific initiative with the University at Buffalo’s Center for Integrated Global Biomedical Sciences includes collaboration on a global program to advance cannabinoid sciences implementation research and safety for both supplement and biomedical use of cannabinoids. The objective of the partnership is to identify optimal approaches to advance the safe use of cannabinoid-containing products and identify the gaps in current knowledge.
This growing acceptance of cannabis, and specifically CBD, isn’t likely to slow and has sparked the explosion of new CBD-infused products and brands within the consumer-packaged goods (“CPG”) space. Industry leaders in this explosive growth market are positioned for exponential growth.
For more information about The Alkaline Water Company, please visit The Alkaline Water Company.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/QPo4W). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased solubility and physical stability of proteins. And while the technology produces unparalleled optimization results, it provides other benefits as well.”
To view the full article, visit: https://ibn.fm/5qPG1
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant facility. According to the company, the move will provide production and process improvements that will result in a reliable, scalable, reproducible and stable drug product suitable for storage, shipment and patient use. “The successful completion of our manufacturing technology transfer represents a major milestone for Genprex,” said Genprex president and CEO Rodney Varner in the press release. “We are delighted to collaborate with leading, global CDMOs that have enabled us to complete the successful engineering batch. We are now focused on the completion of commercial scale production of REQORSA, for use in our two upcoming clinical trials. At the same time, our clinical group is engaging with clinical trial sites who will recruit and treat patients related to our clinical trials.”
To view the full press release, visit http://ibn.fm/BVPes
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Energy Fuels Inc (NYSE American:UUUU) traded at a new 52-week high today of $2.99. This new high was reached on above average trading volume as 4 million shares traded hands, while the average 30-day volume is approximately 2.2 million shares.
Energy Fuels is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. The Company also produces vanadium.
Energy Fuels Inc has overhead space with shares priced $2.60, or 18.7% below the average consensus analyst price target of $3.20.
In the past 52 weeks, Energy Fuels Inc share prices are bracketed by a low of $0.78 and a high of $2.99 and is now at $2.60, 234% above that low price.
Receive IBN`s Technical Indicator Alerts
To stay connected with our complimentary IBN alerts, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading producer of uranium in the United States, recently announced a corporate update and financial results for the quarter ended Sept. 30, 2020 (https://ibn.fm/CEDLQ). In addition to being debt free, Energy Fuels had working capital of $44.7 million at the end of Q3 2020, which is a 17% increase over Q2 2020. An article discussing Energy Fuels’ ability to achieve a debt-free status quotes the company’s president and CEO Mark S. Chalmers, who stated, “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free. Being debt free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare earth element initiative we are pursuing. We have a number of opportunities in front of us right now, any one of which could result in significant cash flows for the company.”
To view the full article, visit https://ibn.fm/rebL4
About Energy Fuels Inc.
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the potential to recover rare earth elements at its White Mesa Mill. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD), the parent company of Vocal, a proprietary creator platform, today announced that it has converted its 10,000th freemium creator to a paid Vocal+ subscriber, a milestone achieved several weeks ahead of management’s year-end target. According to the update, Creatd has expanded its Vocal+ premium subscriber base by over 33% in the last three weeks alone, while experiencing record low subscriber acquisition costs. “With the Vocal platform having crossed 10,000 Vocal+ paid subscribers, coupled with a more focused, more accountable sales strategy, I am enthusiastic about our ability to increase our average contract price as well as the number of clients who will engage our services in 2021,” said Laurie Weisberg, Creatd’s chief operating officer.
To view the full press release, visit http://ibn.fm/BPBVg
About Creatd Inc.
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology platform is Vocal; Vocal provides creators of all shapes and sizes, from bloggers to podcasters, and more, with best-in-class storytelling tools, safe and curated communities, and the opportunity to monetize their content. With 34 owned and operated communities, Vocal enables creators to connect to their ideal audiences and to partner with the brands that want to reach those audiences. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44%, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25% in the size of their tumors,” CNS Pharmaceuticals CEO John Climaco told the webinar audience.
To view the full article, visit: https://ibn.fm/UGq02
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
